Navigation Links
Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 12, 2007 - Geron Corporation's (Nasdaq:GERN) telomerase inhibitor cancer drug, GRN163L, has demonstrated good pharmacokinetics and tolerability in its ongoing Phase I/II trial involving patients with chronic lymphocytic leukemia (CLL), according to data presented today by Alan Colowick, M.D., M.P.H., the company's president, oncology, at the Pan Pacific Lymphoma Conference in Maui, Hawaii.

Favorable Pharmacokinetics; Pharmacodynamics Consistent with Expectations

A pharmacokinetic analysis of three patients in the highest dose cohort (cohort 4, 160 mg/m2 IV/week) has shown transient peak plasma concentrations of GRN163L of approximately 10 ug/ml. This and other data indicate that the drug continues to exhibit favorable pharmacokinetic properties that are linear with respect to the doses tested so far.

Up to the current dose levels, no significant changes in telomerase activity or telomere length in the bulk circulating CLL cells of treated patients have been observed. These pharmacodynamic results are consistent with expectations because of the relatively short exposure of CLL cells in patients' blood to concentrations of drug capable of inhibiting telomerase.

Good Tolerability Profile

With dosing and accrual to cohort 4 continuing, patients treated at the current dose levels have tolerated the drug well, and the maximum tolerated dose has not yet been identified. Grade 1-2 partial thromboplastin time (aPTT) prolongation has been observed, and one patient each has experienced Grade 3 and Grade 4 thrombocytopenia.

Clinical Course

One patient in cohort 4 has completed two cycles of treatment, and stable disease has been observed. A second patient has had clinical findings consistent with tumor lysis syndrome, a transient metabolic abnormality resulting from the rapid destruction of malignant cells. This patient experienced a transie
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
2. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Telomerase Presentations at the AACR 2007 Annual Meeting
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
8. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
9. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
10. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:5/4/2015)... LOS ANGELES , May 4, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... phase 1b aldoxorubicin combination studies pairing aldoxorubicin with ... doses of gemcitabine or ifosfamide with escalating doses ... tolerated, and even at the lowest dose level ...
(Date:5/4/2015)... , May 4, 2015 Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for quarter ending March ... 14, 2015 and will host a conference call ...
(Date:5/4/2015)... , May 4, 2015  Verus Healthcare, Inc. ... acquisition of CPAP Care Club in 2012.  Since that ... within the durable medical equipment (DME) industry by 1,000%.  ... for their CPAP supply needs and processes nearly 14,000 ... this company three years ago, the systems and processes ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3Verus Healthcare Celebrates 1,000% Growth on Third Anniversary 2
(Date:5/4/2015)... 04, 2015 Each year, the Susan G. ... funds and awareness for breast cancer. This year, Dr. Mark ... featured as the entertainment sponsor for the 25th annual Susan ... 9 at the Lenox Square Mall. , The Komen organization ... to raise $1.2 million. Perimeter Plastic Surgery has not only ...
(Date:5/4/2015)... 04, 2015 Johnson & Wales University (JWU) ... and science academic center on Wednesday, April 22. , Johnson ... land made available by the re-alignment of Interstate-195. JWU’s new ... Friendship and Chestnut streets in Providence, is scheduled to be ... parcel of land the university purchased in 2012. , “It ...
(Date:5/4/2015)... 2015 The Lymphoma Research Foundation (LRF) ... funding innovative lymphoma research and serving the lymphoma community ... and patient services – is set to host its ... in West Orange, NJ on June 1, 2015. Since ... research programs through LRF. , This year, the Lymphoma ...
(Date:5/4/2015)... Fla. (PRWEB) May 04, 2015 ... Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke ... Target: Stroke Honor Roll. The award recognizes the ... patients receive the most appropriate treatment according to ... scientific evidence. , To receive the Gold Plus ...
(Date:5/4/2015)... The U.S. healthcare worker shortage crisis is expected ... senior citizens (1) and 27 million Obamacare-insured Americans (2) ... Additionally, as older healthcare employees retire, there will be ... Census Bureau, the number of American workers 65 and ... those 25 to 54 will likely increase 2%. (3) ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4
... 10 Charlotte,s VR Mergers and,Acquisitions has just ... fixture in Laurinburg, NC. VR Charlotte links business ... the transaction were,not disclosed., Established in 1965, ... there since it opened. Todd, the owner since ...
... AURORA, Ohio, Dec. 10 PartsSource, the nation,s ... equipment has,been recognized as a 2007 Pillar Award ... to companies that have distinguished themselves,through leading by ... others., "My initial vision for PartsSource was ...
... (Dec. 10, 2007) Climate change will affect national ... world, in some cases altering conditions so severely that ... planet, according to a study presented at the U.N. ... International (CI), the University of Wisconsin and the University ...
... Institute researcher Jeff Tyner, Ph.D., has created a way to ... myeloid leukemia using an assay that yields results in just ... Society of Hematology annual meeting in Atlanta, on Monday, Dec. ... assay, called RAPID, because it rapidly delivers the information, has ...
... (Amex: ANX ), a biopharmaceutical research and ... the treatment,of cancer and infectious diseases, announced today ... scheduled to present at the 2007 RBC,Capital Markets ... Better Drugs &,Novel Approaches To Cancer Therapy on ...
... Resources Professional Brings Diverse Expertise, MIAMI, Dec. ... products to healthcare providers, is pleased,to announce that ... President of,Human Resources. Ms. Lopez was most recently ... Johnson Company. Her 17-year career began,in Human Resources ...
Cached Medicine News:Health News:New study shows world's protected areas threatened by climate change 2Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference 2Health News:Novis Pharmaceuticals Hires Lisa Lopez 2
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B1 Biological Safety Cabinet...
Built-in, motor-driven internal calibration mass for convenient Touch-key calibration. Also capable of touch-key calibration with external weights. Built-in RS232 Interface, Shimadzu WindowsDirect ...
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Medicine Products: